Dietary isolated isoflavone supplements for peri- and postmenopausal women: Risks and questionable benefits;Risiken und fraglicher Nutzen von Nahrungsergänzungsmitteln mit isolierten Isoflavonen für Frauen in und nach der Menopause

Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz

Volumn 56, Issue 2, 2013, Pages 277-284

  Andres, S ^a   Lampen, A ^a  

^a Abteilung für Lebensmittelsicherheit   (Germany)

Author keywords

Breast cancer; Dietary supplements; Keyword: Isoflavones; Postmenopausal women; Soy

Indexed keywords

ISOFLAVONE DERIVATIVE;

ARTICLE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DIET SUPPLEMENTATION; DRUG EFFECT; FEMALE; HUMAN; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; RISK ASSESSMENT; THYROID DISEASE;

ADMINISTRATION, ORAL; BREAST NEOPLASMS; DIETARY SUPPLEMENTS; FEMALE; HUMANS; ISOFLAVONES; POSTMENOPAUSE; RISK ASSESSMENT; THYROID DISEASES;

EID: 84874080794     PISSN: 14369990     EISSN: 14371588     Source Type: Journal    
DOI: 10.1007/s00103-012-1604-2     Document Type: Article

References (50)

1. Andres S, Abraham K, Appel KE, Lampen A (2011) Risks and benefits of dietary isoflavones for cancer. Crit Rev Toxicol 41:463-506
2. Mortensen A, Kulling SE, Schwartz H et al (2009) Analytical and compositional aspects of isoflavones in food and their biological effects. Mol Nutr Food Res 53:S266-S309
3. Lunny CA, Fraser SN (2010) The use of complementary and alternative medicines among a sample of Canadian menopausal-aged women. J Midwifery Womens Health 55:335-343
4. Mahady GB, Parrot J, Lee C et al (2003) Botanical dietary supplement use in peri- and postmenopausal women. Menopause 10:65-72
5. Harris PF, Remington PL, Trentham-Dietz A et al (2002) Prevalence and treatment of menopausal symptoms among breast cancer survivors. J Pain Symptom Manage 23:501-509
6. Lammersfeld CA, King J, Walker S et al (2009) Prevalence, sources, and predictors of soy consumption in breast cancer. Nutr J 8:2
7. SKLM (2006) Isoflavone als Phytoestrogene in Nahrungsergä nzungsmitteln und diätetischen Lebensmitteln für besondere medizinische Zwecke, DFG - Senatskommission zur Beurteilung der gesundheitlichen Unbedenklichkeit von Lebensmitteln (SKLM). http://www.dfg.de/download/pdf/dfg- im-profil/reden-stellungnahmen/2006/sklm-phytoestrogene-28112006.pdf
8. BfR (2007) Isolierte Isoflavone sind nicht ohne Risiko, Aktualisierte Stellungnahme Nr. 039/2007 des BfR vom 3. April 2007, Bundesinstitut für Risikobewertung (BfR). http://www.bfr.bund.de/cm/343/isolierte-isoflavone-sind- nicht-ohne-risiko.pdf
9. Klein CB, King AA (2007) Genistein genotoxicity: critical considerations of in vitro exposure dose. Toxicol Appl Pharmacol 224:1-11
10. Canderelli R, Leccesse LA, Miller NL, Unruh DJ (2007) Benefits of hormone replacement therapy in postmenopausal women. J Am Acad Nurse Pract 19:635-641
11. Helferich WG, Andrade JE, Hoagland MS (2008) Phytoestrogens and breast cancer: a complex story. Inflammopharmacology 16:219-226
12. Jacobs A, Wegewitz U, Sommerfeld C et al (2009) Efficacy of isoflavones in relieving vasomotor menopausal symptoms: a systematic review. Mol Nutr Food Res 53:1084-1097
13. Lethaby AE, Brown J, Marjoribanks J et al (2007) Phytoestrogens for vasomotor menopausal symptoms. Cochrane Database Syst Rev CD001395
14. EFSA (2011) Scientific Opinion on the substantiation of health claims related to soy isoflavones and protection of DNA, proteins and lipids from oxidative damage (ID 1286, 4245), maintenance of normal blood LDL-cholesterol concentrations (ID 1135, 1704a, 3093a), reduction of vasomotor symptoms associated with menopause (ID 1654, 1704b, 2140, 3093b, 3154, 3590), maintenance of normal skin tonicity (ID 1704a), contribution to normal hair growth (ID 1704a, 4254), "cardiovascular health" (ID 3587), treatment of prostate cancer (ID 3588) and "upper respiratory tract" (ID 3589) pursuant to Article 13(1) of Regulation (EC) No 1924/2006; European Food Safety Authority (EFSA); EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). http://www.efsa.europa.eu/en/efsajournal/doc/2264.pdf. EFSA J 9:2264
15. Evans M, Elliott JG, Sharma P et al (2011) The effect of synthetic genistein on menopause symptom management in healthy postmenopausal women: a multi-center, randomized, placebo-controlled study. Maturitas 68:189-196
16. Cassidy A, Albertazzi P, Lise Nielsen I et al (2006) Critical review of health effects of soyabean phyto-oestrogens in post-menopausal women. Proc Nutr Soc 65:76-92
17. EFSA (2009) Scientific Opinion on the substantiation of health claims related to soy isoflavones and maintenance of bone mineral density (ID 1655) pursuant to Article 13(1) of Regulation (EC) No 1924/2006; European Food Safety Authority (EFSA); EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). http://www.efsa.europa.eu/it/scdocs/doc/1270.pdf. EFSA J 7:1270
18. Castelo-Branco C, Cancelo Hidalgo MJ (2011) Isoflavones: effects on bone health. Climacteric 14:204-211
19. Taku K, Melby MK, Nishi N et al (2011) Soy isoflavones for osteoporosis: an evidence-based approach. Maturitas 70:333-338
20. Wei P, Liu M, Chen Y, Chen DC (2012) Systematic review of soy isoflavone supplements on osteoporosis in women. Asian Pac J Trop Med 5:243-248
21. Dong JY, Qin LQ (2011) Soy isoflavones consumption and risk of breast cancer incidence or recurrence: a meta-analysis of prospective studies. Breast Cancer Res Treat 125:315-323
22. Patisaul HB, Jefferson W (2010) The pros and cons of phytoestrogens. Front Neuroendocrinol 31:400-419
23. Aso T, Uchiyama S, Matsumura Y et al (2012) A natural S-equol supplement alleviates hot flushes and other menopausal symptoms in equol nonproducing postmenopausal Japanese women. J Womens Health (Larchmt) 21:92-100
24. Choi EJ, Kim GH (2011) Anticancer mechanism of equol in 7,12-dimethylbenz(a)anthracene-treated animals. Int J Oncol 39:747-754
25. Goodman MT, Shvetsov YB, Wilkens LR et al (2009) Urinary phytoestrogen excretion and postmenopausal breast cancer risk: the multiethnic cohort study. Cancer Prev Res (Phila) 2:887-894
26. Jackson RL, Greiwe JS, Schwen RJ (2011) Emerging evidence of the health benefits of S-equol, an estrogen receptor beta agonist. Nutr Rev 69:432-448
27. Tousen Y, Ezaki J, Fujii Y et al (2011) Natural S-equol decreases bone resorption in postmenopausal, non-equol-producing Japanese women: a pilot randomized, placebo-controlled trial. Menopause 18:563-574
28. Yoneda T, Ueno T, Uchiyama S (2011) S-equol and the fermented soy product SE5-OH containing S-equol similarly decrease ovariectomy-induced increase in rat tail skin temperature in an animal model of hot flushes. Menopause 18:814-820
29. Tempfer CB, Froese G, Heinze G et al (2009) Side effects of phytoestrogens: a meta-analysis of randomized trials. Am J Med 122:939-946
30. L'Hocine L, Boye JI (2007) Allergenicity of soybean: new developments in identification of allergenic proteins, cross-reactivities and hypoallergenization technologies. Crit Rev Food Sci Nutr 47:127-143
31. Patrick L (2008) Iodine: deficiency and therapeutic considerations. Altern Med Rev 13:116-127
32. Rajah TT, Du N, Drews N, Cohn R (2009) Genistein in the presence of 17beta-estradiol inhibits proliferation of ERbeta breast cancer cells. Pharmacology 84:68-73
33. Cline JM, Wood CE (2009) Estrogen/isoflavone interactions in cynomolgus macaques (Macaca fascicularis). Am J Primatol 71:722-731
34. Hooper L, Madhavan G, Tice JA et al (2010) Effects of isoflavones on breast density in pre- and post-menopausal women: a systematic review and meta-analysis of randomized controlled trials. Hum Reprod Update 16:745-760
35. Khan SA, Chatterton RT, Michel N et al (2012) Soy isoflavone supplementation for breast cancer risk reduction: a randomized phase II trial. Cancer Prev Res (Phila) 5:309-319
36. Singh SP, Wahajuddin, Raju KS et al (2012) Reduced bioavailability of tamoxifen and its metabolite 4-hydroxytamoxifen after oral administration with biochanin A (an isoflavone) in rats. Phytother Res 26:303-307
37. Du M, Yang X, Hartman J A et al (2012) Low-dose dietary genistein negates the therapeutic effect of tamoxifen in athymic nude mice. Carcinogenesis 33:895-901
38. Guha N, Kwan ML, Quesenberry CP Jr et al (2009) Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors: the Life After Cancer Epidemiology study. Breast Cancer Res Treat 118:395-405
39. Shu XO, Zheng Y, Cai H et al (2009) Soy food intake and breast cancer survival. JAMA 302:2437-2443
40. Kang X, Zhang Q, Wang S et al (2010) Effect of soy isoflavones on breast cancer recurrence and death for patients receiving adjuvant endocrine therapy. CMAJ 182:1857-1862
41. Caan BJ, Natarajan L, Parker B et al (2011) Soy food consumption and breast cancer prognosis. Cancer Epidemiol Biomarkers Prev 20:854-858
42. Al-Azzawi F, Wahab M (2010) Effectiveness of phytoestrogens in climacteric medicine. Ann N Y Acad Sci 1205:262-267
43. This P, Cremoux P de, Leclercq G, Jacquot Y (2011) A critical view of the effects of phytoestrogens on hot flashes and breast cancer risk. Maturitas 70:222-226
44. Mahady GB (2005) Do soy isoflavones cause endometrial hyperplasia? Nutr Rev 63:392-397
45. D'Anna R, Cannata ML, Marini H et al (2009) Effects of the phytoestrogen genistein on hot flushes, endometrium, and vaginal epithelium in postmenopausal women: a 2-year randomized, double-blind, placebo-controlled study. Menopause 16:301-306
46. NAMS (2011) The role of soy isoflavones in menopausal health: report of the North American Menopause Society/Wulf H. Utian translational science symposium in Chicago, IL (October 2010). Menopause 18:732-753
47. Pampaloni B, Bartolini S, Bartolini E et al (2009) Absorption and bioeffects of an isoflavone-based supplementation in postmenopausal women. Clin Cases Miner Bone Metab 6:254-260
48. Steinberg FM, Murray MJ, Lewis RD et al (2011) Clinical outcomes of a 2-y soy isoflavone supplementation in menopausal women. Am J Clin Nutr 93:356-367
49. Messina M, Redmond G (2006) Effects of soy protein and soybean isoflavones on thyroid function in healthy adults and hypothyroid patients: a review of the relevant literature. Thyroid 16:249-258
50. Sathyapalan T, Manuchehri AM, Thatcher N J et al (2011) The effect of soy phytoestrogen supplementation on thyroid status and cardiovascular risk markers in patients with subclinical hypothyroidism: a randomized, double-blind, crossover study. J Clin Endocrinol Metab 96:1442-1449